500013-42-3

Basic information

• Product Name: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE
• Synonyms: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE;benzyl 4-(2-(tert-butoxycarbonyl)aminoethyl)piperazine-1-carboxylate
• CAS NO: 500013-42-3
• Molecular Formula: C₁₉H₂₉N₃O₄
• Molecular Weight: 363.45
• Mol File: 500013-42-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(500013-42-3)
• EPA Substance Registry System: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(500013-42-3)

Safety Data

• Hazardous Substances Data: 500013-42-3(Hazardous Substances Data)

Usage

Type of Compound

Piperazine derivative

Functional Groups

Carbobenzyloxy (CBZ) and tert-butyloxycarbonyl (BOC) protecting groups

Purpose

Used in organic synthesis and pharmaceutical research

Application

Intermediate in the synthesis of various pharmaceuticals and bioactive molecules

Usage

Development of potential drug candidates

Additional Applications

Production of peptides, peptidomimetics, and other organic compounds

Protecting Groups

Prevent unwanted side reactions during chemical reactions

Nitrogen Atom

CBZ protecting group attached

Amino Group

BOC protecting group attached

Upstream product

• 500013-41-2 benzyl 4-(2-bromoethyl)piperazine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 104740-55-8 4-(2-aminoethyl)-1-piperazinecarboxylic acid phenylmethyl ester 
• 501-53-1 benzyl chloroformate 
• 100450-84-8 N-[phenylmethylidene]-2-piperazin-1-ylethanamine 
• 140-31-8 aminoethylpiperazine 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 

Downstream Products

• 1710768-30-1 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin- binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).

Design, Synthesis, and Evaluation of Lipopeptide Conjugates of Mercaptoundecahydrododecaborate for Boron Neutron Capture Therapy

We developed new 10B carriers for boron neutron capture therapy (BNCT) that can effectively transport and accumulate boron clusters into cells. These carriers consist of a lipopeptide, mercaptoundecahydrododecaborate (BSH), and a disulfide linker. The carriers were conceived according to the structure of pepducin, a membrane-penetrating lipopeptide targeting protease-activated receptor 1 (PAR1). To improve the membrane permeability of BSH, the structure was optimized using various lipopeptides possessing different peptides and lipid moieties. These synthesized lipopeptides were conjugated with BSH and evaluated for intracellular uptake using T98G glioblastoma cells. Among them, the most effectively incorporated and accumulated in the cells was compound 5 a, which contains a peptide of 13 residues derived from the intracellular third loop of PAR1 and a palmitoyl group. For further improvement of 10B accumulation in cells, the introduction of an amine linker was investigated; intracellular uptake similar to that of 5 a was observed for compound 14, which has a piperazine linker. Both compounds 5 a and 14 showed a stronger radiosensitizing effect than BSH along on T98G cells under mixed-neutron beam irradiation. The results demonstrate that lipopeptide conjugation is effective for enhancing intracellular delivery and accumulation of BSH and improving the cytotoxic effect of BNCT.

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: A comparative study

Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) and has been approved for the treatment of haematological malignancies, such as chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenstr?m's macroglobulinemia. The covalent and irreversible nature of its molecular mode of action allows identification and monitoring of its target in an activity-based protein profiling (ABPP) setting. Fluorescent and biotinylated ibrutinib derivatives have appeared in the literature in recent years to monitor BTK in vitro and in situ. The work described here complements this existing methodology and pertains a comparative study on the efficacy of direct and two-step bioorthogonal ABPP of BTK.

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.